H2020Индивидуална стипендия2019–2021

THERAPROBES · Biodegradable fluorescent nanoprobes for early detection of (pre)malignant lesions of the gastrointestinal tract

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2019-09-01 → 2021-08-31
Финансиране от ЕС: 187 572 €
Участници: 1
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Биоразградими флуоресцентни нанозонди се тестват за по-точно откриване на предракови изменения в стомашно-чревния тракт по време на ендоскопия. Това помага за ранна диагностика и по-точно определяне на границите на пораженията, което подобрява шансовете за успешно лечение.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Biodegradable fluorescent nanoprobes for early detection of (pre)malignant lesions of the gastrointestinal tract

The problem/issue being addressed: “THERAPROBES” is about the timely and accurate diagnosis of (pre)malignant gastrointestinal (GI)-tract lesions, which is critical for patient survival. Early detection of asymptomatic disease of the GI tract significantly improves the chance of curative intervention by 50−80% as compared to poor five-year survival rates for symptomatic advanced malignant disease. Importance for Society: Regular endoscopic surveillance in high-risk patients misses 5−25% of (pre)malignant lesions – the clinically most relevant marker for malignant progression. This clinically significant miss rate is due to the subtle appearance of such lesions under white-light endoscopy and sampling errors inherent to a random-biopsy surveillance paradigm, which increases inter-operator variability and compromises diagnostic accuracy. Even when the malignant disease is detected, lack of sensitive contrast agents impairs delineation of the true extent of the lesion. These factors decrease the physician’s ability to achieve successful therapeutic intervention through resection or ablation. Consequently, ~33% of GI-tract lesions progress or recur at or near the therapeutic site, commonly requiring aggressive yet often non-curative, systemic treatments negatively impacting the patients’ quality of life. There is an unmet clinical need for endoscopic optical imaging approaches that reliably detect (pre)malignant GI-tract lesions with high sensitivity and specificity and thus improve standardization, diagnostic accuracy, and therapeutic adequacy. Overall objectives: Touse biodegradable, fluorescent silica nanoprobes (FSNs), which are 50-100 nm in size that provide real-time visualization of (pre)malignant GI-tract lesions over a range of scales during routine endoscopy. Since tumour accumulation of FSNs is governed by size-dependent extra-vascularization due to increased vascular permeability, no active targeting is needed, making these imaging agents ubiquitously applicable. Endoscopy augmented with FSNs has tremendous potential for better outcomes particularly in high-risk patients by accurately diagnosing and directing treatment specifically to early lesions at a time when patients are still amenable to curative therapeutic intervention.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Accurate diagnosis of (pre)malignant gastrointestinal (GI)-tract lesions is critical for patient survival. Early detection of asymptomatic disease of the GItract improves the chance of curative intervention by 50−80% as compared to poor five-year survival rates for symptomatic advanced malignant disease. Regular endoscopic surveillance in high-risk patients misses 25% of (pre)malignant lesions – the most clinically relevant marker for malignant progression. This clinically significant miss rate is due to the subtle appearance of such lesions under white-light endoscopy and sampling errors inherent to a random-biopsy surveillance paradigm, which increases inter-operator variability and compromises diagnostic accuracy. Even when malignant disease is detected, lack of sensitive contrast agents compromises delineation of the true extent of the lesion. These factors decrease the physician’s ability to achieve successful therapeutic intervention through resection or ablation. About 33% of GI-tract lesions progress or recur at or near the therapeutic site, commonly requiring aggressive yet often non-curative, systemic treatments negatively impacting the patients’ quality of life. There is an unmet clinical need for endoscopic optical imaging approaches that reliably detect those lesions with high sensitivity and specificity. To develop a clinically viable strategy, I propose to use biodegradable, fluorescent silica nanoprobes (FSN) that provide real-time visualization of the lesions over a range of scales during routine endoscopy. Since FSNs accumulate at the tumor sites solely due to their size and increased vascular permeability, no active targeting is needed, making these imaging agents ubiquitously applicable. Endoscopy augmented with FSNs has tremendous potential for better outcomes particularly in high-risk patients by accurately diagnosing and directing treatment specifically to early lesions at a time when patients are amenable to curative therapeutic intervention.

Оригинален текст от CORDIS (на английски).

Участници

PERCUROS BV · 's-Gravenhage (Den Haag)КоординаторНидерландия